
United Kingdom Diabetes Devices and Therapeutics Market Investment Opportunities – Analysis & Market Size by Diagnosis and Monitoring Devices, Therapeutics, Combination Drugs, Route of Administration, Type of Diabetes, Distribution Channels, End User, Co
Description
According to BioIntel360, diabetes market in United Kingdom is expected to grow by 8.7% on annual basis to reach US$7,050.1 million in 2025.
The diabetes market in the country has experienced robust growth during 2020-2024, achieving a CAGR of 9.5%. This upward trajectory is expected to continue, with the market forecast to grow at a CAGR of 7.2% during 2025-2029. By the end of 2029, the diabetes market is projected to expand from its 2024 value of USD 6,487.0 million to approximately USD 10,094.1 million.
Key Trends and Drivers in the United Kingdom
The UK diabetes devices and therapeutics market is being reshaped by increased CGM adoption, enhanced digital health integration, growth in connected therapeutic devices, and evolving regulatory frameworks. Over the next 2–4 years, these trends are projected to intensify, leading to improved patient management and fostering innovation within the diabetes care landscape.
Expand Use of Continuous Glucose Monitoring Systems
• UK healthcare providers are integrating continuous glucose monitoring (CGM) systems into diabetes management programs across both NHS and private settings. Instances include NHS pilot initiatives in London and Manchester, where CGM data supports patient monitoring.
• Updated NHS reimbursement guidelines and clinical recommendations from UK health authorities have promoted broader CGM use. Advances in MedTech and data-driven clinical practices support the transition from traditional finger-prick testing to real-time monitoring.
• The adoption of CGM systems is expected to intensify as reimbursement structures evolve and clinical evidence accumulates. Increased real-time monitoring is anticipated to improve treatment adjustments and patient outcomes over the medium term.
Integrate Digital Health Solutions for Remote Monitoring
• Digital platforms are being deployed to support remote patient monitoring and telemedicine in diabetes care. Recent initiatives within the NHS have implemented digital dashboards that consolidate patient data for enhanced clinical decision-making.
• Government digital health strategies and increased funding for telemedicine drive the integration of remote monitoring tools. Broader shifts in healthcare delivery models and MedTech investments are supporting digital solutions.
• Integration of digital health platforms is projected to expand, improving connectivity between patients and healthcare providers. This trend is expected to intensify, contributing to more efficient patient management and data-driven clinical decisions.
Enhance Therapeutic Delivery Systems
• The market is witnessing the introduction of connected therapeutic devices, such as smart insulin pens and automated insulin pumps. Clinical trials in several UK hospitals have evaluated these systems for dosing accuracy and treatment adherence.
• Advances in device technology and supportive clinical data from recent UK studies are key drivers. Adjustments in reimbursement models and increased MedTech investments further facilitate the uptake of these innovative systems.
• Adopting advanced therapeutic delivery systems is expected to grow steadily as clinical guidelines and reimbursement policies adapt. More precise dosing and improved adherence may enhance diabetes management across the UK.
Regulatory and Reimbursement Frameworks
• UK regulatory bodies update approval processes and reimbursement frameworks to accommodate new diabetes devices and therapies. Recent policy reviews and NHS documents indicate streamlined pathways for device integration into clinical practice.
• Broader healthcare reform and cost-containment initiatives are prompting these regulatory adjustments. Recent publications emphasize the need for clear reimbursement strategies to support innovative diabetes care solutions.
• A more defined regulatory framework is expected to boost market confidence and encourage further investments in diabetes technologies. Increased clarity in reimbursement processes will likely promote market growth and improved patient access to advanced devices.
Competitive Landscape in the United Kingdom
The UK diabetes devices and therapeutics market comprises a dynamic mix of multinational leaders and emerging local innovators. Recent strategic partnerships, mergers, and acquisitions are reshaping competitive dynamics, with an increasing emphasis on digital integration and regulatory alignment.
In the coming years, heightened competition and strategic collaborations are expected to drive innovation and enhance patient management solutions across the UK diabetes care sector.
Evaluate Current Market Conditions
• The UK market features a mix of established multinational companies and emerging local innovators. The structured NHS framework provides clear pathways for device adoption and reimbursement, supporting market stability.
Key Players and New Entrants
• Major multinational manufacturers maintain a strong presence through long-term partnerships with the NHS and private healthcare providers. These companies offer comprehensive portfolios encompassing both monitoring devices and therapeutic systems.
• Local startups and technology firms are entering the market with digital health solutions designed specifically for UK patient populations. Recent market analyses indicate that these entrants are gaining traction through pilot projects and collaborations with clinical institutions.
Review Recent Partnerships, Mergers, and Acquisitions
• Recent publications detail strategic partnerships between established firms and digital health innovators to enhance device connectivity and data integration. Mergers and acquisitions reported over the past 12 months suggest efforts to consolidate technological expertise and expand market reach.
• These collaborative activities contribute to a more interconnected market, where shared innovation supports efficient product development and regulatory compliance. Such consolidation creates a more focused competitive landscape in which established and emerging companies are positioning themselves.
Future Competitive Dynamics (Next 2–4 Years)
• The competitive landscape is expected to evolve with increased consolidation and strategic alliances, especially as digital integration becomes a focal point. Enhanced competition is anticipated between firms focused on traditional devices and those prioritizing innovative digital solutions.
• Intensified competition will likely drive further innovation and refined product offerings, resulting in more targeted patient management strategies. Over the next 2–4 years, strategic collaborations and market consolidation are expected to solidify competitive positioning across the UK.
This report provides a detailed data-centric analysis of the diabetes industry in United Kingdom, covering market opportunities and analysis across a range of diagnosis and monitoring devices, therapeutics, domains. With over 50+ KPIs at the country level, this report provides a comprehensive understanding of diabetes market dynamics, market size and forecast, and market share statistics.
BioIntel360’s research methodology is based on industry best practices. Its unbiased analysis leverages a proprietary analytics platform to offer a detailed view of emerging business and investment market opportunities.
Scope
This report provides an in-depth, data-centric analysis of the United Kingdom diabetes devices and therapeutics market 2020-2029. Below is a summary of key market segments:
Diabetes Devices and Therapeutics Market Share by Category
• Diagnosis and Monitoring Devices
• Therapeutics
Diabetes Devices and Therapeutics Market Share by Diagnosis and Monitoring Devices
• Blood Glucose Monitoring Devices
• Insulin Delivery Devices
• Diabetes Management and Mobile Applications
• Artificial Pancreas Devices
Diabetes Devices and Therapeutics Market Share by Blood Glucose Monitoring Devices
• Self-Monitoring Blood Glucose Devices
• Continuous Blood Glucose Monitoring Devices
• Test Strips
• Lancets
Diabetes Devices and Therapeutics Market Share by Insulin Delivery Devices
• Insulin Pumps
• Insulin Pens
• Insulin Syringes
Diabetes Devices and Therapeutics Market Share by Therapeutics
• Oral Anti-Diabetic Drugs
• Insulin
• Non-Insulin Injectable Drugs
• Combination Drugs
Diabetes Devices and Therapeutics Market Share by Oral Anti-Diabetic Drugs
• Alpha-Glucosidase Inhibitors
• DPP-4 Inhibitors
• SGLT-2 Inhibitors
Diabetes Devices and Therapeutics Market Share by Insulin
• Basal or Long-Acting
• Bolus or Fast-Acting
• Traditional Human Insulin Drugs
• Insulin Biosimilars
Diabetes Devices and Therapeutics Market Share by Non-Insulin Injectable Drugs
• GLP-1 Receptor Agonists
• Amylin Analogue
Diabetes Devices and Therapeutics Market Share by Combination Drugs
• Combination Insulin
• Oral Combination
Diabetes Devices and Therapeutics Market Share by Route of Administration
• Subcutaneous
• Intravenous
• Others
Diabetes Devices and Therapeutics Market Share by Type of Diabetes
• Type 1 Diabetes
• Type 2 Diabetes
Diabetes Devices and Therapeutics Market Share by Distribution Channels
• Online Pharmacies
• Hospital Pharmacies
• Retail Pharmacies
Diabetes Devices and Therapeutics Market Share by End User
• Hospitals
• Diabetes Clinics
• Homecare
Reasons to Buy
• Comprehensive understanding of market structure and dynamics: Gain a detailed view of the diabetes devices and therapeutics market, including category-level segmentation (Diagnosis & Monitoring Devices and Therapeutics) and sub-segmentation by product type, route of administration, type of diabetes, distribution channel, and end user.
• Identify high-growth segments and strategic investment areas: Use segment-wise market sizing and forecasting to identify opportunities in areas such as continuous glucose monitoring, insulin delivery technologies, oral anti-diabetic drugs, and biosimilars. Tailor your market entry or expansion strategies accordingly.
• Benchmark performance across distribution and care settings: Access share analysis across online, hospital, and retail pharmacies, and evaluate usage patterns across hospitals, diabetes clinics, and homecare to support channel-specific planning and resource allocation.
The diabetes market in the country has experienced robust growth during 2020-2024, achieving a CAGR of 9.5%. This upward trajectory is expected to continue, with the market forecast to grow at a CAGR of 7.2% during 2025-2029. By the end of 2029, the diabetes market is projected to expand from its 2024 value of USD 6,487.0 million to approximately USD 10,094.1 million.
Key Trends and Drivers in the United Kingdom
The UK diabetes devices and therapeutics market is being reshaped by increased CGM adoption, enhanced digital health integration, growth in connected therapeutic devices, and evolving regulatory frameworks. Over the next 2–4 years, these trends are projected to intensify, leading to improved patient management and fostering innovation within the diabetes care landscape.
Expand Use of Continuous Glucose Monitoring Systems
• UK healthcare providers are integrating continuous glucose monitoring (CGM) systems into diabetes management programs across both NHS and private settings. Instances include NHS pilot initiatives in London and Manchester, where CGM data supports patient monitoring.
• Updated NHS reimbursement guidelines and clinical recommendations from UK health authorities have promoted broader CGM use. Advances in MedTech and data-driven clinical practices support the transition from traditional finger-prick testing to real-time monitoring.
• The adoption of CGM systems is expected to intensify as reimbursement structures evolve and clinical evidence accumulates. Increased real-time monitoring is anticipated to improve treatment adjustments and patient outcomes over the medium term.
Integrate Digital Health Solutions for Remote Monitoring
• Digital platforms are being deployed to support remote patient monitoring and telemedicine in diabetes care. Recent initiatives within the NHS have implemented digital dashboards that consolidate patient data for enhanced clinical decision-making.
• Government digital health strategies and increased funding for telemedicine drive the integration of remote monitoring tools. Broader shifts in healthcare delivery models and MedTech investments are supporting digital solutions.
• Integration of digital health platforms is projected to expand, improving connectivity between patients and healthcare providers. This trend is expected to intensify, contributing to more efficient patient management and data-driven clinical decisions.
Enhance Therapeutic Delivery Systems
• The market is witnessing the introduction of connected therapeutic devices, such as smart insulin pens and automated insulin pumps. Clinical trials in several UK hospitals have evaluated these systems for dosing accuracy and treatment adherence.
• Advances in device technology and supportive clinical data from recent UK studies are key drivers. Adjustments in reimbursement models and increased MedTech investments further facilitate the uptake of these innovative systems.
• Adopting advanced therapeutic delivery systems is expected to grow steadily as clinical guidelines and reimbursement policies adapt. More precise dosing and improved adherence may enhance diabetes management across the UK.
Regulatory and Reimbursement Frameworks
• UK regulatory bodies update approval processes and reimbursement frameworks to accommodate new diabetes devices and therapies. Recent policy reviews and NHS documents indicate streamlined pathways for device integration into clinical practice.
• Broader healthcare reform and cost-containment initiatives are prompting these regulatory adjustments. Recent publications emphasize the need for clear reimbursement strategies to support innovative diabetes care solutions.
• A more defined regulatory framework is expected to boost market confidence and encourage further investments in diabetes technologies. Increased clarity in reimbursement processes will likely promote market growth and improved patient access to advanced devices.
Competitive Landscape in the United Kingdom
The UK diabetes devices and therapeutics market comprises a dynamic mix of multinational leaders and emerging local innovators. Recent strategic partnerships, mergers, and acquisitions are reshaping competitive dynamics, with an increasing emphasis on digital integration and regulatory alignment.
In the coming years, heightened competition and strategic collaborations are expected to drive innovation and enhance patient management solutions across the UK diabetes care sector.
Evaluate Current Market Conditions
• The UK market features a mix of established multinational companies and emerging local innovators. The structured NHS framework provides clear pathways for device adoption and reimbursement, supporting market stability.
Key Players and New Entrants
• Major multinational manufacturers maintain a strong presence through long-term partnerships with the NHS and private healthcare providers. These companies offer comprehensive portfolios encompassing both monitoring devices and therapeutic systems.
• Local startups and technology firms are entering the market with digital health solutions designed specifically for UK patient populations. Recent market analyses indicate that these entrants are gaining traction through pilot projects and collaborations with clinical institutions.
Review Recent Partnerships, Mergers, and Acquisitions
• Recent publications detail strategic partnerships between established firms and digital health innovators to enhance device connectivity and data integration. Mergers and acquisitions reported over the past 12 months suggest efforts to consolidate technological expertise and expand market reach.
• These collaborative activities contribute to a more interconnected market, where shared innovation supports efficient product development and regulatory compliance. Such consolidation creates a more focused competitive landscape in which established and emerging companies are positioning themselves.
Future Competitive Dynamics (Next 2–4 Years)
• The competitive landscape is expected to evolve with increased consolidation and strategic alliances, especially as digital integration becomes a focal point. Enhanced competition is anticipated between firms focused on traditional devices and those prioritizing innovative digital solutions.
• Intensified competition will likely drive further innovation and refined product offerings, resulting in more targeted patient management strategies. Over the next 2–4 years, strategic collaborations and market consolidation are expected to solidify competitive positioning across the UK.
This report provides a detailed data-centric analysis of the diabetes industry in United Kingdom, covering market opportunities and analysis across a range of diagnosis and monitoring devices, therapeutics, domains. With over 50+ KPIs at the country level, this report provides a comprehensive understanding of diabetes market dynamics, market size and forecast, and market share statistics.
BioIntel360’s research methodology is based on industry best practices. Its unbiased analysis leverages a proprietary analytics platform to offer a detailed view of emerging business and investment market opportunities.
Scope
This report provides an in-depth, data-centric analysis of the United Kingdom diabetes devices and therapeutics market 2020-2029. Below is a summary of key market segments:
Diabetes Devices and Therapeutics Market Share by Category
• Diagnosis and Monitoring Devices
• Therapeutics
Diabetes Devices and Therapeutics Market Share by Diagnosis and Monitoring Devices
• Blood Glucose Monitoring Devices
• Insulin Delivery Devices
• Diabetes Management and Mobile Applications
• Artificial Pancreas Devices
Diabetes Devices and Therapeutics Market Share by Blood Glucose Monitoring Devices
• Self-Monitoring Blood Glucose Devices
• Continuous Blood Glucose Monitoring Devices
• Test Strips
• Lancets
Diabetes Devices and Therapeutics Market Share by Insulin Delivery Devices
• Insulin Pumps
• Insulin Pens
• Insulin Syringes
Diabetes Devices and Therapeutics Market Share by Therapeutics
• Oral Anti-Diabetic Drugs
• Insulin
• Non-Insulin Injectable Drugs
• Combination Drugs
Diabetes Devices and Therapeutics Market Share by Oral Anti-Diabetic Drugs
• Alpha-Glucosidase Inhibitors
• DPP-4 Inhibitors
• SGLT-2 Inhibitors
Diabetes Devices and Therapeutics Market Share by Insulin
• Basal or Long-Acting
• Bolus or Fast-Acting
• Traditional Human Insulin Drugs
• Insulin Biosimilars
Diabetes Devices and Therapeutics Market Share by Non-Insulin Injectable Drugs
• GLP-1 Receptor Agonists
• Amylin Analogue
Diabetes Devices and Therapeutics Market Share by Combination Drugs
• Combination Insulin
• Oral Combination
Diabetes Devices and Therapeutics Market Share by Route of Administration
• Subcutaneous
• Intravenous
• Others
Diabetes Devices and Therapeutics Market Share by Type of Diabetes
• Type 1 Diabetes
• Type 2 Diabetes
Diabetes Devices and Therapeutics Market Share by Distribution Channels
• Online Pharmacies
• Hospital Pharmacies
• Retail Pharmacies
Diabetes Devices and Therapeutics Market Share by End User
• Hospitals
• Diabetes Clinics
• Homecare
Reasons to Buy
• Comprehensive understanding of market structure and dynamics: Gain a detailed view of the diabetes devices and therapeutics market, including category-level segmentation (Diagnosis & Monitoring Devices and Therapeutics) and sub-segmentation by product type, route of administration, type of diabetes, distribution channel, and end user.
• Identify high-growth segments and strategic investment areas: Use segment-wise market sizing and forecasting to identify opportunities in areas such as continuous glucose monitoring, insulin delivery technologies, oral anti-diabetic drugs, and biosimilars. Tailor your market entry or expansion strategies accordingly.
• Benchmark performance across distribution and care settings: Access share analysis across online, hospital, and retail pharmacies, and evaluate usage patterns across hospitals, diabetes clinics, and homecare to support channel-specific planning and resource allocation.
Table of Contents
72 Pages
- 1 United Kingdom Diabetes Devices and Therapeutics Market Size and Forecast, 2020-2029
- 2 United Kingdom Diabetes Devices and Therapeutics Market Share by Category, 2020-2029
- 2.1 United Kingdom Diabetes Devices and Therapeutics Market Size by Diagnosis and Monitoring Devices, 2020-2029
- 2.2 United Kingdom Diabetes Devices and Therapeutics Market Size by Therapeutics, 2020-2029
- 3 United Kingdom Diabetes Devices and Therapeutics Market Share by Diagnosis and Monitoring Devices, 2020-2029
- 3.1 Diabetes Devices and Therapeutics Market Size by Blood Glucose Monitoring Devices, 2020-2029
- 3.2 Diabetes Devices and Therapeutics Market Size by Insulin Delivery Devices, 2020-2029
- 3.3 Diabetes Devices and Therapeutics Market Size by Diabetes Management and Mobile Applications, 2020-2029
- 3.4 Diabetes Devices and Therapeutics Market Size by Artificial Pancreas Devices, 2020-2029
- 4 United Kingdom Diabetes Devices and Therapeutics Market Share by Blood Glucose Monitoring Devices, 2020-2029
- 4.1 Diabetes Devices and Therapeutics Market Size by Self-Monitoring Blood Glucose Devices, 2020-2029
- 4.2 Diabetes Devices and Therapeutics Market Size by Continuous Blood Glucose Monitoring Devices, 2020-2029
- 4.3 Diabetes Devices and Therapeutics Market Size by Test Strips, 2020-2029
- 4.4 Diabetes Devices and Therapeutics Market Size by Lancets, 2020-2029
- 5 United Kingdom Diabetes Devices and Therapeutics Market Share by Insulin Delivery Devices, 2020-2029
- 5.1 Diabetes Devices and Therapeutics Market Size by Insulin Pumps, 2020-2029
- 5.2 Diabetes Devices and Therapeutics Market Size by Insulin Pens, 2020-2029
- 5.3 Diabetes Devices and Therapeutics Market Size by Insulin Syringes, 2020-2029
- 6 United Kingdom Diabetes Devices and Therapeutics Market Share by Therapeutics, 2020-2029
- 6.1 Diabetes Devices and Therapeutics Market Size by Oral Anti-Diabetic Drugs, 2020-2029
- 6.2 Diabetes Devices and Therapeutics Market Size by Insulin, 2020-2029
- 6.3 Diabetes Devices and Therapeutics Market Size by Non-Insulin Injectable Drugs, 2020-2029
- 6.4 Diabetes Devices and Therapeutics Market Size by Combination Drugs, 2020-2029
- 7 United Kingdom Diabetes Devices and Therapeutics Market Share by Oral Anti-Diabetic Drugs, 2020-2029
- 7.1 Diabetes Devices and Therapeutics Market Size by Alpha-Glucosidase Inhibitors, 2020-2029
- 7.2 Diabetes Devices and Therapeutics Market Size by DPP-4 Inhibitors, 2020-2029
- 7.3 Diabetes Devices and Therapeutics Market Size by SGLT-2 Inhibitors, 2020-2029
- 8 United Kingdom Diabetes Devices and Therapeutics Market Share by Insulin, 2020-2029
- 8.1 Diabetes Devices and Therapeutics Market Size by Basal or Long-Acting, 2020-2029
- 8.2 Diabetes Devices and Therapeutics Market Size by Bolus or Fast-Acting, 2020-2029
- 8.3 Diabetes Devices and Therapeutics Market Size by Traditional Human Insulin Drugs, 2020-2029
- 8.4 Diabetes Devices and Therapeutics Market Size by Insulin Biosimilars, 2020-2029
- 9 United Kingdom Diabetes Devices and Therapeutics Market Share by Non-Insulin Injectable Drugs, 2020-2029
- 9.1 Diabetes Devices and Therapeutics Market Size by GLP-1 Receptor Agonists, 2020-2029
- 9.2 Diabetes Devices and Therapeutics Market Size by Amylin Analogue, 2020-2029
- 10 United Kingdom Diabetes Devices and Therapeutics Market Share by Combination Drugs, 2020-2029
- 10.1 Diabetes Devices and Therapeutics Market Size by Combination Insulin, 2020-2029
- 10.2 Diabetes Devices and Therapeutics Market Size by Oral Combination, 2020-2029
- 11 United Kingdom Diabetes Devices and Therapeutics Market Share by Route of Administration, 2020-2029
- 11.1 Diabetes Devices and Therapeutics Market Size by Subcutaneous, 2020-2029
- 11.2 Diabetes Devices and Therapeutics Market Size by Intravenous, 2020-2029
- 11.3 Diabetes Devices and Therapeutics Market Size by Others, 2020-2029
- 12 United Kingdom Diabetes Devices and Therapeutics Market Share by Type of Diabetes, 2020-2029
- 12.1 Diabetes Devices and Therapeutics Market Size by Type 2 Diabetes, 2020-2029
- 12.2 Diabetes Devices and Therapeutics Market Size by Type 1 Diabetes, 2020-2029
- 13 United Kingdom Diabetes Devices and Therapeutics Market Share by Distribution Channels, 2020-2029
- 13.1 Diabetes Devices and Therapeutics Market Size by Online Pharmacies, 2020-2029
- 13.2 Diabetes Devices and Therapeutics Market Size by Hospital Pharmacies, 2020-2029
- 13.3 Diabetes Devices and Therapeutics Market Size by Retail Pharmacies, 2020-2029
- 14 United Kingdom Diabetes Devices and Therapeutics Market Share by End User, 2020-2029
- 14.1 Diabetes Devices and Therapeutics Market Size by Hospitals, 2020-2029
- 14.2 Diabetes Devices and Therapeutics Market Size by Diabetes Clinics, 2020-2029
- 14.3 Diabetes Devices and Therapeutics Market Size by Homecare, 2020-2029
- Table 1: United Kingdom Diabetes Devices and Therapeutics Market Size by Value (US$ Million) 2020-2029
- Table 2: United Kingdom Diabetes Devices and Therapeutics Market Size by Diagnosis and Monitoring Devices, by Value (US$ Million), 2020-2029
- Table 3: United Kingdom Diabetes Devices and Therapeutics Market Size by Therapeutics, by Value (US$ Million) 2020-2029
- Table 4: United Kingdom Diabetes Devices and Therapeutics Market Size by Blood Glucose Monitoring Devices, by Value (US$ Million) 2020-2029
- Table 5: United Kingdom Diabetes Devices and Therapeutics Market Size by Insulin Delivery Devices, by Value (US$ Million) 2020-2029
- Table 6: United Kingdom Diabetes Devices and Therapeutics Market Size by Diabetes Management and Mobile Applications, by Value (US$ Million) 2020-2029
- Table 7: United Kingdom Diabetes Devices and Therapeutics Market Size by Artificial Pancreas Devices, by Value (US$ Million) 2020-2029
- Table 8: United Kingdom Diabetes Devices and Therapeutics Market Size by Self-Monitoring Blood Glucose Devices, by Value (US$ Million) 2020-2029
- Table 9: United Kingdom Diabetes Devices and Therapeutics Market Size by Continuous Blood Glucose Monitoring Devices, by Value (US$ Million) 2020-2029
- Table 10: United Kingdom Diabetes Devices and Therapeutics Market Size by Test Strips, by Value (US$ Million) 2020-2029
- Table 11: United Kingdom Diabetes Devices and Therapeutics Market Size by Lancets, by Value (US$ Million) 2020-2029
- Table 12: United Kingdom Diabetes Devices and Therapeutics Market Size by Insulin Pumps, by Value (US$ Million) 2020-2029
- Table 13: United Kingdom Diabetes Devices and Therapeutics Market Size by Insulin Pens, by Value (US$ Million) 2020-2029
- Table 14: United Kingdom Diabetes Devices and Therapeutics Market Size by Insulin Syringes, by Value (US$ Million) 2020-2029
- Table 15: United Kingdom Diabetes Devices and Therapeutics Market Size by Oral Anti-Diabetic Drugs, by Value (US$ Million), 2020-2029
- Table 16: United Kingdom Diabetes Devices and Therapeutics Market Size by Insulin, by Value (US$ Million), 2020-2029
- Table 17: United Kingdom Diabetes Devices and Therapeutics Market Size by Non-Insulin Injectable Drugs, by Value (US$ Million), 2020-2029
- Table 18: United Kingdom Diabetes Devices and Therapeutics Market Size by Combination Drugs, by Value (US$ Million), 2020-2029
- Table 19: United Kingdom Diabetes Devices and Therapeutics Market Size by Alpha-Glucosidase Inhibitors (US$ Million), 2020-2029
- Table 20: United Kingdom Diabetes Devices and Therapeutics Market Size by DPP-4 Inhibitors (US$ Million), 2020-2029
- Table 21: United Kingdom Diabetes Devices and Therapeutics Market Size by SGLT-2 Inhibitors (US$ Million), 2020-2029
- Table 22: United Kingdom Diabetes Devices and Therapeutics Market Size by Basal or Long-Acting, by Value (US$ Million), 2020-2029
- Table 23: United Kingdom Diabetes Devices and Therapeutics Market Size by Bolus or Fast-Acting, by Value (US$ Million), 2020-2029
- Table 24: United Kingdom Diabetes Devices and Therapeutics Market Size by Traditional Human Insulin Drugs, by Value (US$ Million), 2020-2029
- Table 25: United Kingdom Diabetes Devices and Therapeutics Market Size by Insulin Biosimilars, by Value (US$ Million), 2020-2029
- Table 26: United Kingdom Diabetes Devices and Therapeutics Market Size by GLP-1 Receptor Agonists, by Value (US$ Million), 2020-2029
- Table 27: United Kingdom Diabetes Devices and Therapeutics Market Size by Amylin Analogue, by Value (US$ Million), 2020-2029
- Table 28: United Kingdom Diabetes Devices and Therapeutics Market Size by Combination Insulin, by Value (US$ Million), 2020-2029
- Table 29: United Kingdom Diabetes Devices and Therapeutics Market Size by Oral Combination, by Value (US$ Million), 2020-2029
- Table 30: United Kingdom Diabetes Devices and Therapeutics Market Size by Subcutaneous, by Value (US$ Million), 2020-2029
- Table 31: United Kingdom Diabetes Devices and Therapeutics Market Size by Intravenous, by Value (US$ Million), 2020-2029
- Table 32: United Kingdom Diabetes Devices and Therapeutics Market Size by Others, by Value (US$ Million), 2020-2029
- Table 33: United Kingdom Diabetes Devices and Therapeutics Market Size by Type 2 Diabetes, by Value (US$ Million), 2020-2029
- Table 34: United Kingdom Diabetes Devices and Therapeutics Market Size by Type 1 Diabetes, by Value (US$ Million), 2020-2029
- Table 35: United Kingdom Diabetes Devices and Therapeutics Market Size by Online Pharmacies, by Value (US$ Million), 2020-2029
- Table 36: United Kingdom Diabetes Devices and Therapeutics Market Size by Hospital Pharmacies, by Value (US$ Million), 2020-2029
- Table 37: United Kingdom Diabetes Devices and Therapeutics Market Size by Retail Pharmacies, by Value (US$ Million), 2020-2029
- Table 38: United Kingdom Diabetes Devices and Therapeutics Market Size by Hospitals, by Value (US$ Million), 2020-2029
- Table 39: United Kingdom Diabetes Devices and Therapeutics Market Size by Diabetes Clinics, by Value (US$ Million), 2020-2029
- Table 40: United Kingdom Diabetes Devices and Therapeutics Market Size by Homecare, by Value (US$ Million), 2020-2029
- Figure 1: United Kingdom Diabetes Devices and Therapeutics Market Size by Value (US$ Million) 2020-2029
- Figure 2: United Kingdom Diabetes Devices and Therapeutics Market Share by Category (%), 2020-2029
- Figure 3: United Kingdom Diabetes Devices and Therapeutics Market Size by Diagnosis and Monitoring Devices, by Value (US$ Million), 2020-2029
- Figure 4: United Kingdom Diabetes Devices and Therapeutics Market Size by Therapeutics, by Value (US$ Million) 2020-2029
- Figure 5: United Kingdom Diabetes Devices and Therapeutics Market Share by Diagnosis and Monitoring Devices (%), 2020-2029
- Figure 6: United Kingdom Diabetes Devices and Therapeutics Market Size by Blood Glucose Monitoring Devices, by Value (US$ Million) 2020-2029
- Figure 7: United Kingdom Diabetes Devices and Therapeutics Market Size, by Insulin Delivery Devices, by Value (US$ Million) 2020-2029
- Figure 8: United Kingdom Diabetes Devices and Therapeutics Market Size by Diabetes Management and Mobile Applications, by Value (US$ Million) 2020-2029
- Figure 9: United Kingdom Diabetes Devices and Therapeutics Market Size, by Artificial Pancreas Devices, by Value (US$ Million) 2020-2029
- Figure 10: United Kingdom Diabetes Devices and Therapeutics Market Share by Blood Glucose Monitoring Devices (%), 2020-2029
- Figure 11: United Kingdom Diabetes Devices and Therapeutics Market Size by Self-Monitoring Blood Glucose Devices, by Value (US$ Million) 2020-2029
- Figure 12: United Kingdom Diabetes Devices and Therapeutics Market Size by Continuous Blood Glucose Monitoring Devices, by Value (US$ Million) 2020-2029
- Figure 13: United Kingdom Diabetes Devices and Therapeutics Market Size by Test Strips, by Value (US$ Million) 2020-2029
- Figure 14: United Kingdom Diabetes Devices and Therapeutics Market Size by Lancets, by Value (US$ Million) 2020-2029
- Figure 15: United Kingdom Diabetes Devices and Therapeutics Market Share by Insulin Delivery Devices (%), 2020-2029
- Figure 16: United Kingdom Diabetes Devices and Therapeutics Market Share by Insulin Pumps, by Value (US$ Million) 2020-2029
- Figure 17: United Kingdom Diabetes Devices and Therapeutics Market Share by Insulin Pens, by Value (US$ Million) 2020-2029
- Figure 18: United Kingdom Diabetes Devices and Therapeutics Market Share by Insulin Syringes, by Value (US$ Million) 2020-2029
- Figure 19: United Kingdom Diabetes Devices and Therapeutics Market Share by Therapeutics (%), 2020-2029
- Figure 20: United Kingdom Diabetes Devices and Therapeutics Market Size by Oral Anti-Diabetic Drugs, by Value (US$ Million), 2020-2029
- Figure 21: United Kingdom Diabetes Devices and Therapeutics Market Size by Insulin, by Value (US$ Million), 2020-2029
- Figure 22: United Kingdom Diabetes Devices and Therapeutics Market Size by Non-Insulin Injectable Drugs, by Value (US$ Million), 2020-2029
- Figure 23: United Kingdom Diabetes Devices and Therapeutics Market Size by Combination Drugs, by Value (US$ Million), 2020-2029
- Figure 24: United Kingdom Diabetes Devices and Therapeutics Market Share by Oral Anti-Diabetic Drugs (%), 2020-2029
- Figure 25: United Kingdom Diabetes Devices and Therapeutics Market Size by Alpha-Glucosidase Inhibitors (US$ Million), 2020-2029
- Figure 26: United Kingdom Diabetes Devices and Therapeutics Market Size by DPP-4 Inhibitors (US$ Million), 2020-2029
- Figure 27: United Kingdom Diabetes Devices and Therapeutics Market Size by SGLT-2 Inhibitors (US$ Million), 2020-2029
- Figure 28: United Kingdom Diabetes Devices and Therapeutics Market Share by Insulin (%), 2020-2029
- Figure 29: United Kingdom Diabetes Devices and Therapeutics Market Size by Basal or Long-Acting, by Value (US$ Million), 2020-2029
- Figure 30: United Kingdom Diabetes Devices and Therapeutics Market Size by Bolus or Fast-Acting, by Value (US$ Million), 2020-2029
- Figure 31: United Kingdom Diabetes Devices and Therapeutics Market Size by Traditional Human Insulin Drugs, by Value (US$ Million), 2020-2029
- Figure 32: United Kingdom Diabetes Devices and Therapeutics Market Size by Insulin Biosimilars, by Value (US$ Million), 2020-2029
- Figure 33: United Kingdom Diabetes Devices and Therapeutics Market Share by Non-Insulin Injectable Drugs (%), 2020-2029
- Figure 34: United Kingdom Diabetes Devices and Therapeutics Market Size by GLP-1 Receptor Agonists, by Value (US$ Million), 2020-2029
- Figure 35: United Kingdom Diabetes Devices and Therapeutics Market Size by Amylin Analogue, by Value (US$ Million), 2020-2029
- Figure 36: United Kingdom Diabetes Devices and Therapeutics Market Share by Combination Drugs (%), 2020-2029
- Figure 37: United Kingdom Diabetes Devices and Therapeutics Market Size by Combination Insulin, by Value (US$ Million), 2020-2029
- Figure 38: United Kingdom Diabetes Devices and Therapeutics Market Size by Oral Combination, by Value (US$ Million), 2020-2029
- Figure 39: United Kingdom Diabetes Devices and Therapeutics Market Share by Route of Administration (%), 2020-2029
- Figure 40: United Kingdom Diabetes Devices and Therapeutics Market Size by Subcutaneous, by Value (US$ Million), 2020-2029
- Figure 41: United Kingdom Diabetes Devices and Therapeutics Market Size by Intravenous, by Value (US$ Million), 2020-2029
- Figure 42: United Kingdom Diabetes Devices and Therapeutics Market Size by Others, by Value (US$ Million), 2020-2029
- Figure 43: United Kingdom Diabetes Devices and Therapeutics Market Share by Type of Diabetes (%), 2020-2029
- Figure 44: United Kingdom Diabetes Devices and Therapeutics Market Size by Type 2 Diabetes, by Value (US$ Million), 2020-2029
- Figure 45: United Kingdom Diabetes Devices and Therapeutics Market Size by Type 1 Diabetes, by Value (US$ Million), 2020-2029
- Figure 46: United Kingdom Diabetes Devices and Therapeutics Market Share by Distribution Channels (%), 2020-2029
- Figure 47: United Kingdom Diabetes Devices and Therapeutics Market Size by Online Pharmacies, by Value (US$ Million), 2020-2029
- Figure 48: United Kingdom Diabetes Devices and Therapeutics Market Size by Hospital Pharmacies, by Value (US$ Million), 2020-2029
- Figure 49: United Kingdom Diabetes Devices and Therapeutics Market Size by Retail Pharmacies, by Value (US$ Million), 2020-2029
- Figure 50: United Kingdom Diabetes Devices and Therapeutics Market Share by End User (%), 2020-2029
- Figure 51: United Kingdom Diabetes Devices and Therapeutics Market Size by Hospitals, by Value (US$ Million), 2020-2029
- Figure 52: United Kingdom Diabetes Devices and Therapeutics Market Size by Diabetes Clinics, by Value (US$ Million), 2020-2029
- Figure 53: United Kingdom Diabetes Devices and Therapeutics Market Size by Homecare, by Value (US$ Million), 2020-2029
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.